Comprehensive SWOT analysis reveals Gilead Sciences Inc's strategic positioning in the pharmaceutical industry. Financial ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

US biotech major Gilead Sciences was trading nearly 2% higher in pre-market on Thursday after announcing its third-quarter ...

Regeneron Pharmaceuticals and Amgen, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance. Gilead ...

In this article, we will take a look at the 10 Best Pharma Stocks To Buy Right Now.

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today. The company’s ...

The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.